GRK4 Polymorphisms Blood Pressure Response to Candesartan
1 other identifier
interventional
500
1 country
1
Brief Summary
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Jul 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2012
CompletedFirst Posted
Study publicly available on registry
June 27, 2012
CompletedStudy Start
First participant enrolled
July 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2015
CompletedNovember 18, 2014
June 1, 2013
2 years
June 24, 2012
November 17, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension
two years
Study Arms (1)
candesartan
NO INTERVENTIONAll antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
Interventions
To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
Eligibility Criteria
You may qualify if:
- men and women with mild to moderate essential hypertension in southwestern Han Chinese
You may not qualify if:
- subjects unwilling to participate or subjects did not have all measurement required,
- subjects who were on medications, which affect blood pressure or
- whose DNA failed to amplify and 8 with errors in Mendelian segregation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Cardiology, Daping Hospital, The Third Military Medical University
Chongqing, 400042, China
Related Publications (2)
Cai Y, Yang Y, Chen X, He D, Zhang X, Wen X, Hu J, Fu C, Qiu D, Jose PA, Zeng C, Zhou L. Circulating "LncPPARdelta" From Monocytes as a Novel Biomarker for Coronary Artery Diseases. Medicine (Baltimore). 2016 Feb;95(6):e2360. doi: 10.1097/MD.0000000000002360.
PMID: 26871769DERIVEDYang Y, Cai Y, Wu G, Chen X, Liu Y, Wang X, Yu J, Li C, Chen X, Jose PA, Zhou L, Zeng C. Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci (Lond). 2015 Oct 1;129(8):675-85. doi: 10.1042/CS20150121. Epub 2015 Jun 11.
PMID: 26201019DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Zeng Chunyu, Doctor
TMMU
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Cardiovascular Diseases; Institute of Cardiovascular Diseases; Daping Hospital;
Study Record Dates
First Submitted
June 24, 2012
First Posted
June 27, 2012
Study Start
July 1, 2013
Primary Completion
July 1, 2015
Study Completion
July 1, 2015
Last Updated
November 18, 2014
Record last verified: 2013-06